First patients sought for new hope in Tough-to-Treat blood cancer
NCT ID NCT07426757
Summary
This is the first study in people for a new drug called PF-07994525, developed by Pfizer. It aims to find a safe dose and see if the drug shows early signs of fighting cancer in adults with advanced multiple myeloma that has stopped responding to other treatments. The study will start by testing different dose levels in a small group of patients to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.